Should Airway Hyper-Responsiveness Be Included in the Definition of Clinical Remission With Biologic Therapy in Severe Asthma.

Autor:	Lipworth B; Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom. Electronic address: b.j.lipworth@dundee.ac.uk., Kuo CR; Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom., Stewart K; Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom., Chan R; Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom.
Jazyk:	angličtina
Zdroj:	The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2024 Apr; Vol. 12 (4), pp. 904-907. Date of Electronic Publication: 2023 Dec 12.
DOI:	10.1016/j.jaip.2023.12.013
Abstrakt:	Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics. (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu